{
    "clinical_study": {
        "@rank": "25168", 
        "biospec_descr": {
            "textblock": "Blood samples"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Longitudinal study of patients with rheumatoid arthritis comparing measures of disease\n      activity with blood samples."
        }, 
        "brief_title": "Discovering the Antecedents of Rheumatoid Arthritis Flare", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "80% of patients living with rheumatoid arthritis can expect fluctuations in their symptoms\n      over time.  Dramatic increases in disease activity are considered flare.  This study will\n      follow patients with increased risk for flare prospectively for one year.  Serial\n      questionnaires and disease activity scores will be compared to blood samples to better\n      understand the molecular phenotype of rheumatoid arthritis flares."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  2010 criteria for Rheumatoid Arthritis\n\n          -  Swelling of at least one joint and or elevated acute phase reactants\n\n          -  Greater than or equal to 40 years old or less than or equal to 65 year old female sex\n\n          -  cyclic citrullinated peptide antibody + in the past 12 months\n\n        Exclusion Criteria:\n\n          -  hemoglobin < 9\n\n          -  white blood cell count < 3.5\n\n          -  Diagnosis of any active malignancy within the last 3 years besides non-melanomatous\n             skin cancer\n\n          -  Diagnosis of diabetes and requires insulin\n\n          -  HIV+, Hep B S Ag+, Hep C polymerase chain reaction +\n\n          -  Untreated latent tuberculosis\n\n          -  Diagnosis of any additional systemic autoimmune connective tissue disease\n\n          -  Inability to reliably complete study requirements\n\n          -  History, physical, social or laboratory findings suggestive of any other medical or\n             psychological condition that would, in the opinion of the principal investigator,\n             make the candidate ineligible for the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Rheumatoid Arthritis"
            }
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02051114", 
            "org_study_id": "DOR-0833"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Rheumatoid arthritis", 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "The Rockefeller University Hospital"
            }, 
            "investigator": {
                "last_name": "Dana E Orange, MD, MS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Discovering the Antecedents of Rheumatoid Arthritis Flare", 
        "overall_contact": {
            "email": "RUcares@rockefeller.edu", 
            "last_name": "Lauren Corregano", 
            "phone": "1-800-782-2737"
        }, 
        "overall_official": {
            "affiliation": "The Rockefeller University Hospital", 
            "last_name": "Dana E Orange, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood drawn at various times throughout one year will be correlated with fluctuations in RA disease activity.", 
            "measure": "RNA transcripts that correlate with rheumatoid arthritis disease activity", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02051114"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rockefeller University", 
            "investigator_full_name": "Dana Orange", 
            "investigator_title": "Instructor in Clinical Investigation", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Rockefeller University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rockefeller University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}